Medical/Pharmaceuticals
Lunit Showcases AI-Powered Cancer Ecosystem at APEC High-Level Meeting on Health and the Economy and World Bio Summit 2025
Lunit highlights global leadership in cancer AI alongside world health experts with dedicated APEC HLMHE session and WBS 2025 Leaders' Dialogue SEOUL, South Korea, Sept. 16, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announc...
2025-09-16 21:00
5938
Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) today announced that its proprietary next-generation humanized IgG4 monoclonal antibody targeting CD47, ligufalimab (AK117), has been granted Orphan Drug Designation (ODD) by the U.S. FDA for the treatment of acute myeloid leukemia (A...
2025-09-16 10:27
2381
Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the 34th EADV Congress 2025
SAN FRANCISCO and SUZHOU, China, Sept. 15, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metaboli...
2025-09-16 09:00
2801
HitGen Partner BioAge Labs Initiates Phase 1 Clinical Study of BGE-102, a Novel Brain-Penetrant NLRP3 inhibitor
* BGE-102, an orally available, brain-penetrant NLRP3 inhibitor, was developed from a hit compound identified using HitGen's industry-leading DEL technology platform, highlighting the value of DEL to accelerate innovative drug development. * The initiation of the BGE-102 Phase 1 clinical stud...
2025-09-15 21:30
3394
EmeTerm Wearable Device Under Clinical Study at Ohio State Wexner Medical Center Shows Promise for Chronic Nausea Patients
VANCOUVER, BC, Sept. 15, 2025 /PRNewswire/ -- WAT Medical Enterprise Ltd. is proud to announce that its innovative anti-nausea wristband, EmeTerm, has made significant progress in alleviating nausea and vomiting among patients suffering from chronic gastric disorders. A clinical study currently u...
2025-09-15 21:00
3447
Korea reinforces biopharma leadership at Global Bio Conference 2025
SEOUL, South Korea, Sept. 15, 2025 /PRNewswire/ -- This is an article published in The Korea Herald: The Ministry of Food and Drug Safety on Thursday announced its successful hosting of the Global Bio Conference 2025 inSeoul last week, under the theme "Bio, Navigating Infinite Possibilities." T...
2025-09-15 20:30
2113
Sunsred Launches FDA-cleared Red Light Therapy Devices for Wellness Brands Worldwide
SHENZHEN, China, Sept. 15, 2025 /PRNewswire/ -- Shenzhen Sunsred Technology Co., Ltd. is shaking things up in the wellness tech world with its latest lineup of red light therapy devices. As a go-toOEM/ODM red light therapy manufacturer in this space, Sunsred is meeting the huge global demand for ...
2025-09-15 19:00
2191
Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma
HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class P...
2025-09-15 12:11
2493
Phrontline Biopharma Announces First Patient Dosed in Phase 1 Clinical Trial of TJ101
SHANGHAI and SUZHOU, China, Sept. 14, 2025 /PRNewswire/ -- Phrontline Biopharma , a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the com...
2025-09-15 08:00
2015
LakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
BEIJING, Sept. 12, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-12 20:00
5285
Smartee and Shanghai Ninth People's Hospital Win First Prize at Shanghai Science and Technology Progress Awards
SHANGHAI, Sept. 10, 2025 /PRNewswire/ -- Smartee Denti-Technology, a global innovator in invisible orthodontic solutions, together with Shanghai Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine, has been awarded the First Prize of the Shanghai Science and ...
2025-09-12 10:03
2355
Zhimeng Biopharma's Investigational Drug Approved to Initiate Phase 2 Epilepsy Clinical Trial in China
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng Biopharma") announced that its self-developed novel next-generation KCNQ2/3 potassium channel opener, CB03-154, has recently received clinical trial approval from the Center for Drug Evaluation (CDE) ofChina's Nat...
2025-09-12 00:00
2511
Datasea Secures Landmark Agreement for First Acoustic Wearable Technology Contract, Marking Entry into the $1 Trillion Market
Driving the Commercialization of Acoustic Technology in Smart Health Wearables through Solution-Based Service Delivery BEIJING, Sept. 11, 2025 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS), a Nevada -based technology company specializing in acoustic high-tech products and AI multimodal digital solu...
2025-09-11 21:30
3927
GLOBAL FIRST "High-Definition Image": Decoding the "Code of Youth" - LivingPhoenix's POGMENT Collagen Breakthrough Fills Global Gap
CHENGDU, China, Sept. 11, 2025 /PRNewswire/ -- Recently, LivingPhoenix®Regenerative Technologies Development (Chengdu) Co., Ltd. (hereinafter "LivingPhoenix Technology") announced that its independently developed POGMENT triple-helix biomimetic collagen has, for the first time in the world, achi...
2025-09-11 21:27
3191
Lunit Awarded Major National Tender in France, Expanding Access to Breast AI in Public Hospitals
Framework agreement with UniHA enables access to Lunit's breast AI solutions across 1,500+ French public hospitals, in collaboration with Fujifilm SEOUL, South Korea, Sept. 11, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today anno...
2025-09-11 21:00
2923
YolTech Therapeutics Raises $45 Million in Series B Financing Led by AstraZeneca-CICC
SHANGHAI, Sept. 11, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage biotech company pioneering in vivo genome editing therapies, today announced the closing of its approximately$45 million Series B financing led by the AstraZeneca-CICC healthcare investment fund. The proceeds will sup...
2025-09-11 20:05
2394
Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
SYDNEY, Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led by ProfessorSudha Rao at QIMR Berghofer. In this ex vivo study, blood samples from Stage IV HER2-...
2025-09-11 20:00
3799
Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
BEIJING, Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale ...
2025-09-10 21:30
1925
C-Ray Therapeutics Supports Mednovo's Phase III Clinical Trial with First Patient Dosed for Lutetium [177Lu] Oxodotreotide Injection
CHENGDU, China, Sept. 10, 2025 /PRNewswire/ -- August 22, 2025, Mednovo Group Co., Ltd. ("Mednovo") announced that the first patient has been successfully dosed in its Phase III clinical trial of Lutetium [177Lu] Oxodotreotide Injection, a Class 3 targeted radiotherapeutic drug. As the exclusive...
2025-09-10 21:30
2501
LakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
BEIJING, Sept. 10, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB, "LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious ...
2025-09-10 20:10
4764
Week's Top Stories
Most Reposted
SMU School of Accountancy launches Applied AI Track for next generation of accounting and finance professionals
[Picked up by 282 media titles]
2026-10-07 11:50DayOne Files Registration Statement for Proposed Initial Public Offering
[Picked up by 279 media titles]
2026-10-06 05:28Agoda Partners with Marina Bay Sands on Bespoke Flagship Store for Experience-Led Travel
[Picked up by 277 media titles]
2026-10-08 09:50
New Asia Forum Targets US$30 Billion in Investment into the New Asia at Its Inaugural Edition in Bali
[Picked up by 274 media titles]
2026-10-09 13:21Southeast Asia's China travel map is widening, Traveloka platform data shows
[Picked up by 263 media titles]
2026-10-05 11:51Most Read
Nuix Neo Generative AI Framework
2026-10-08 08:02
9127
Silicon Quantum Computing Named to Fast Company's 2026 Next Big Things in Tech List
2026-10-06 19:38
8163
DayOne Files Registration Statement for Proposed Initial Public Offering
2026-10-06 05:28
7981